Tumor Surveillance Technique
Tumor Surveillance Technique - Related Videos
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
0 Views •
2025
Overtreatment is often administered to patients with low-risk prostate cancer; super-active surveillance can help avoid such overtreatment.
03:59
Orthotopic Homograft Tumor Transplantation: A Technique to Generate Pancreatic Tumor Mouse Models
0 Views •
2023
The video explains a stepwise surgical method for orthotopic implantation of a tumor fragment from a cancerous donor to the pancreas of a non-cancerous recipient mice for development of pancreatic cancer. Orthotopically implanted PDAC could recapture the tissue microenvironment of human pancreatic cancers than conventional subcutaneous (SC) models more accurately.
03:50
Irreversible Electroporation: A Technique for Ablating Pancreatic Tumor in Mouse
0 Views •
2023
This video describes the procedure for performing irreversible electroporation (IRE) for non-thermal ablation of pancreatic tumors in mice. Both subcutaneous (SQ) and orthotopic tumors can be successfully treated with IRE in a highly controlled setting, facilitating various studies post-procedure.
01:26
Principles of Disease Surveillance
0 Views •
2025
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
02:31
FFPE Tumor Tissue Macrodissection: A Technique to Obtain Specific Tumorous Tissue from Unstained Specimens
0 Views •
2023
This video describes a method for the manual macrodissection of cancer tissue from unstained tissue specimens to obtain a specific cancer tissue. The tissue section can be processed further to obtain DNA for genome-wide studies on gastrointestinal cancers.
FAQs
Interpretation depends on comparison with baseline findings and on trends observed across repeated assessments. Changes in tumor size, activity, molecular features, or associated biomarkers become more informative when they persist or occur alongside findings from physical examination, imaging, or tissue analysis. This longitudinal comparison helps researchers and clinicians evaluate whether the disease is progressing, recurring, or responding to treatment.
Each assessment provides a different view of tumor status. Imaging can show changes in size or activity, physical examination can identify clinically observable findings, and biomarkers or tissue samples can reveal associated molecular or tissue-level changes. Considering these sources together reduces reliance on a single measurement and supports a more complete assessment of disease development and treatment response.
A single evaluation describes tumor status at a particular moment, whereas surveillance emphasizes change over time. Repeated measurements can reveal progression, recurrence, treatment response, or evolving molecular features that may not be apparent initially. Establishing a baseline and comparing later findings creates longitudinal evidence, making the approach useful for both clinical follow-up and cancer research.
The process begins by documenting baseline findings, followed by scheduled or repeated assessments using appropriate combinations of imaging, physical examination, biomarkers, and tissue samples. Later results are compared with the baseline and with prior observations to identify changes in size, activity, or molecular features. The resulting pattern supports evaluation of disease status, treatment response, or possible recurrence.
Repeated observations generate longitudinal data that can show how tumors change during disease development or after treatment. Imaging, biomarkers, and tissue analyses may document shifts in tumor characteristics over time, allowing investigators to relate those changes to progression or response. These data help characterize tumor evolution and provide a structured basis for studying cancer across multiple time points.
It is useful whenever ongoing comparison is needed after an initial assessment or during cancer management. Serial findings can indicate whether tumor size or activity is changing after treatment, while later deviations from established findings may support evaluation of recurrence. The approach also helps guide follow-up strategies by linking current observations with the patient’s earlier baseline and longitudinal record.
Standardized monitoring makes assessments more consistent across time and, within studies, across participants or research sites. Using comparable approaches to record imaging, examination findings, biomarkers, and tissue results improves the interpretability of longitudinal data. Consistency supports evaluation of treatment response, characterization of disease progression, and development of evidence that can inform more individualized cancer management.